Dartmouth Lead Participation in NCI National Clinical Trials Network

达特茅斯牵头参与 NCI 国家临床试验网络

• 批准号: 8839217
• 负责人: Konstantin H. Dragnev
• 金额: $ 31.95万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-16 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8839217
• 关键词: Address; Adult; Advanced Malignant Neoplasm; Back; Basic Science; Cancer Biology; Cancer Patient; Cancer and Leukemia Group B; Caring; Catchment Area; Clinical; Clinical Oncology; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Comprehensive Cancer Center; Conduct Clinical Trials; Consent; Cooperative Group Program; Development; Diagnosis; Diagnostic; Disease; Education; Eligibility Determination; Engineering; Enrollment; Evaluation; Funding; Funding Opportunities; Future; Geographic Locations; Goals; Gynecologic Oncology Group; Health; Image; Immunology; Industry; Institution; Interdisciplinary Study; Knowledge; Laboratories; Lead; Leadership; Lebanon; Malignant Neoplasms; Medical center; Mission; Monitor; Multi-Institutional Clinical Trial; National Cancer Institute; National Clinical Trials Network; New England; New Hampshire; Norris Cotton Cancer Center; Nursing Research; Oncology Group; Patient Care; Patients; Phase; Positioning Attribute; Preventive; Principal Investigator; Process; Protocols documentation; Radiation Therapy Oncology Group; Randomized; Recording of previous events; Reporting; Request for Applications; Research; Research Infrastructure; Research Personnel; Resource Sharing; Rural; Schools; Science; Scientist; Services; Site; System; Target Populations; Therapeutic; Therapeutic Trials; Translating; Translational Research; Vermont; anticancer research; base; cancer care; cancer imaging; cancer therapy; clinical application; college; community based practice; design; innovation; interest; medical schools; medical specialties; medically underserved population; member; multidisciplinary; patient population; phase III trial; prevent; programs; response; symposium; treatment trial; tumor

DESCRIPTION (provided by applicant): Norris Cotton Cancer Center (NCCC), the keystone of the cancer-related activities of both Dartmouth College, and its Geisel School of Medicine, and Dartmouth-Hitchcock Health, will participate in the NCI's National Clinical Trials Network as a Lead Academic Participating Site. NCCC has a long history of leadership in national cooperative group clinical trials, dating back to serving as an operating center for CALGB, and more recently as a full member of CALGB's successor (the Alliance), RTOG, and COG, and as an Affiliate member of GOG. As the only NCI-designated Comprehensive Cancer Center in northern New England, NCCC currently serves annually over 5,200 new and 30,000 returning cancer patients. NCCC is the specialty academic center for Vermont and New Hampshire, anchoring a network of 17 community- based practice sites across the region and receiving referrals of rare and advanced cancers, the target population for enrollment on innovative clinical. Trials, from a large geographic catchment area. Within Dartmouth, NCCC has a central Office of Clinical Research (OCR) which coordinates full participation in the entire range of available clinical trials. NCCC intends to participate in all 6 pending NCI-designated networks, expanding its prior focus on participation in the Alliance. We anticipate earning annually close to 400 enrollment credits for adult subjects on studies, including a projected 74 consented subjects on interventional therapeutic trial s. Care at DH is organized into 17 designated interdisciplinary disease-based teams which bring together all relevant specialties, 14 on a weekly basis, for new patient conferences at which eligibility for enrollment on clinical trials is assessed routinely. NCCC research nurses assigned to these Clinical Oncology Groups (COGs) are responsible for keeping the teams informed of available trials, and the NCCC clinical trials management system (Velos eResearch) provides the teams reports tracking current enrollment. While highest priority is given to translating NCCC science into clinical application, Dartmouth's size precludes most single-institution studies, and national cooperative group trials are prioritized ahead of industry initiated studies for fulfillment of NCCC's clinical research mission.

描述（由申请人提供）：诺里斯·科顿癌症中心 (NCCC) 是达特茅斯学院及其盖泽尔医学院和达特茅斯希区柯克健康中心癌症相关活动的基石，将参与 NCI 的国家临床试验网络作为主要学术参与网站。 NCCC 在国家合作组临床试验方面具有悠久的领导历史，可以追溯到作为 CALGB 的运营中心，最近作为 CALGB 的继承者（联盟）、RTOG 和 COG 的正式成员以及附属成员GOG 的。作为新英格兰北部唯一一家 NCI 指定的综合癌症中心，NCCC 目前每年为超过 5,200 名新癌症患者和 30,000 名返回癌症患者提供服务。 NCCC 是佛蒙特州和新罕布什尔州的专业学术中心，在该地区建立了一个由 17 个社区实践点组成的网络，并接收罕见和晚期癌症的转诊，这是创新临床注册的目标人群。试验是在一个大的地理区域进行的。在达特茅斯，NCCC 设有临床研究中央办公室 (OCR)，负责协调所有可用临床试验的全面参与。 NCCC 打算参与所有 6 个待定的 NCI 指定网络，扩大其先前对参与联盟的关注。我们预计每年的收入接近 为成人受试者提供 400 个注册学分，其中包括预计 74 名同意参与介入治疗试验的受试者。 DH 的护理分为 17 个指定的跨学科 以疾病为基础的团队，每周 14 次聚集所有相关专业，召开新患者会议，定期评估参加临床试验的资格。分配给这些临床肿瘤学组 (COG) 的 NCCC 研究护士负责让团队了解可用的试验，NCCC 临床试验管理系统 (Velos eResearch) 为团队提供跟踪当前入组情况的报告。虽然最高优先级是将 NCCC 科学转化为临床应用，但达特茅斯的规模排除了大多数单一机构研究，并且国家合作团体试验优先于行业 启动研究以完成 NCCC 的临床研究任务。